MX2023001493A - Composicion farmaceutica de un inhibidor de la acuaporina y metodo para la preparacion de la misma. - Google Patents
Composicion farmaceutica de un inhibidor de la acuaporina y metodo para la preparacion de la misma.Info
- Publication number
- MX2023001493A MX2023001493A MX2023001493A MX2023001493A MX2023001493A MX 2023001493 A MX2023001493 A MX 2023001493A MX 2023001493 A MX2023001493 A MX 2023001493A MX 2023001493 A MX2023001493 A MX 2023001493A MX 2023001493 A MX2023001493 A MX 2023001493A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- preparation
- aquaporin inhibitor
- pharmaceutically acceptable
- aquaporin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 229940121720 Aquaporin inhibitor Drugs 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract 1
- WSHXPHFIHYXZKC-UHFFFAOYSA-N [2-[[3,5-bis(trifluoromethyl)phenyl]carbamoyl]-4-chlorophenyl] dihydrogen phosphate Chemical compound OP(O)(=O)OC1=CC=C(Cl)C=C1C(=O)NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WSHXPHFIHYXZKC-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 229960003194 meglumine Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010779964 | 2020-08-05 | ||
| PCT/CN2021/110506 WO2022028459A1 (en) | 2020-08-05 | 2021-08-04 | Pharmaceutical composition of aquaporin inhibitor and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001493A true MX2023001493A (es) | 2023-06-23 |
Family
ID=80120008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001493A MX2023001493A (es) | 2020-08-05 | 2021-08-04 | Composicion farmaceutica de un inhibidor de la acuaporina y metodo para la preparacion de la misma. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230293556A1 (https=) |
| EP (1) | EP4192442A4 (https=) |
| JP (1) | JP2023536509A (https=) |
| KR (1) | KR20230137284A (https=) |
| CN (1) | CN117337182A (https=) |
| AU (1) | AU2021323181A1 (https=) |
| BR (1) | BR112023002129A2 (https=) |
| CA (1) | CA3187716A1 (https=) |
| IL (1) | IL300341A (https=) |
| MX (1) | MX2023001493A (https=) |
| TW (1) | TW202228714A (https=) |
| WO (1) | WO2022028459A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013169939A2 (en) | 2012-05-08 | 2013-11-14 | Aeromics, Llc | New methods |
| US20160279155A1 (en) | 2013-11-06 | 2016-09-29 | Aeromics, Inc. | Novel formulations |
| US11117909B2 (en) | 2016-05-13 | 2021-09-14 | Aeromics, Inc. | Crystals |
| WO2024208207A1 (zh) * | 2023-04-03 | 2024-10-10 | 拜西欧斯（北京）生物技术有限公司 | 一种双取代萘化合物及其药物组合物和用途 |
| WO2025075479A1 (ko) * | 2023-10-04 | 2025-04-10 | 이화여자대학교 산학협력단 | 아쿠아포린 4 억제제의 심방세동 치료 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2488363C (en) * | 2002-06-06 | 2011-01-04 | Institute Of Medicinal Molecular Design, Inc. | O-substituted hydroxyaryl derivatives |
| WO2008067196A2 (en) * | 2006-11-16 | 2008-06-05 | The Regents Of The University Of California | Methods for identifying inhibitors of solute transporters |
| WO2013169939A2 (en) * | 2012-05-08 | 2013-11-14 | Aeromics, Llc | New methods |
| US20160279155A1 (en) * | 2013-11-06 | 2016-09-29 | Aeromics, Inc. | Novel formulations |
| CA2931550C (en) * | 2013-12-13 | 2023-09-26 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| US11117909B2 (en) * | 2016-05-13 | 2021-09-14 | Aeromics, Inc. | Crystals |
-
2021
- 2021-08-04 EP EP21852147.4A patent/EP4192442A4/en active Pending
- 2021-08-04 AU AU2021323181A patent/AU2021323181A1/en active Pending
- 2021-08-04 US US18/040,618 patent/US20230293556A1/en active Pending
- 2021-08-04 CA CA3187716A patent/CA3187716A1/en active Pending
- 2021-08-04 IL IL300341A patent/IL300341A/en unknown
- 2021-08-04 BR BR112023002129A patent/BR112023002129A2/pt unknown
- 2021-08-04 CN CN202180057413.1A patent/CN117337182A/zh active Pending
- 2021-08-04 JP JP2023508083A patent/JP2023536509A/ja active Pending
- 2021-08-04 WO PCT/CN2021/110506 patent/WO2022028459A1/en not_active Ceased
- 2021-08-04 MX MX2023001493A patent/MX2023001493A/es unknown
- 2021-08-04 KR KR1020237007248A patent/KR20230137284A/ko active Pending
- 2021-08-05 TW TW110128921A patent/TW202228714A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023536509A (ja) | 2023-08-25 |
| CN117337182A (zh) | 2024-01-02 |
| AU2021323181A1 (en) | 2023-03-23 |
| IL300341A (en) | 2023-04-01 |
| EP4192442A1 (en) | 2023-06-14 |
| BR112023002129A2 (pt) | 2023-04-18 |
| US20230293556A1 (en) | 2023-09-21 |
| TW202228714A (zh) | 2022-08-01 |
| CA3187716A1 (en) | 2022-02-10 |
| EP4192442A4 (en) | 2025-03-19 |
| KR20230137284A (ko) | 2023-10-04 |
| WO2022028459A1 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001493A (es) | Composicion farmaceutica de un inhibidor de la acuaporina y metodo para la preparacion de la misma. | |
| MX2022013637A (es) | Nuevos compuestos de triazinoindol. | |
| MX2022014942A (es) | Nuevos compuestos. | |
| MX2023002371A (es) | Derivado de nitrilo que actua como inhibidor de la dipeptidil peptidasa 1 y uso del mismo. | |
| MX2022012896A (es) | Pirrolo[1,2-d][1,2,4]triazin-2-ilacetamidas como inhibidores de la ruta del inflamasoma nlrp3. | |
| EP0189788B1 (de) | Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika | |
| WO1999032463A1 (en) | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | |
| WO2000041698A1 (en) | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | |
| PT1274698E (pt) | Perciquinina, metodo para a sua producao e sua utilizacao como medicamento | |
| US20110046195A1 (en) | Non-Lactone Carbocyclic and Heterocyclic Antagonists and Agonists of Bacterial Quorum Sensing | |
| MA31432B1 (fr) | Metabolites de derives de (thio) carbamoyl-cyclohexane | |
| MX2023003459A (es) | Nuevos compuestos. | |
| MX2025005014A (es) | Inhibidor del inflamosoma nlrp3 y uso de este | |
| EP1274421B1 (de) | Verwendung von MEK-Inhibitoren zur Herstellung eines Arzneimittels gegen Negativstrang-RNA-Viren Infektionen | |
| WO2016080846A1 (en) | Antibacterial compounds | |
| MX2023003576A (es) | Compuesto como inhibidor de la akt cinasa. | |
| WO2022268935A3 (en) | Process for the preparation of nlrp3 inhibitors | |
| MX2025000744A (es) | Preparacion y uso de un derivado de quinazolinona como inhibidor de cinasas | |
| BR0315820A (pt) | Inibidores de integrase de hiv, composições farmacêuticas e métodos para a sua utilização | |
| MX2023014722A (es) | Forma cristalina de tolebrutinib y método de preparación y su uso. | |
| AU639785B2 (en) | Use of substituted beta-hydroxyethylamines as potent inhibitors of the exoenzymes of fungi | |
| MX2023010223A (es) | Derivados de 4-amino-6-oxo-piridazina que modulan la nlrp3. | |
| MX2023010310A (es) | Derivados de 4-alcoxi-6-oxo-piridazina que modulan nlrp3. | |
| MX2023003458A (es) | Nuevos compuestos. | |
| MX2020004588A (es) | Inhibidor de proteasa de doble cabeza. |